



Biodefense: Complementary Roles within DHHS

CDC




- Surveillance and Detection
- Train Local Response Teams
- Maintain Vaccine/Antimicrobial Stockpiles

NIH




- Conduct Basic Research
- Develop Medical Interventions
- Develop Research Infrastructure

FDA




- Regulatory Approval
 - Vaccines
 - Therapeutics
 - Diagnostics

OPHEP



- HHS-Wide Coordination of Emergency Preparedness Activities

NIH Biodefense Research Funding, FY 2000-2006



*Does not include \$47.4M in HHS FYs 2005 and 2006 for nuclear/radiobiology defense research and \$50M in FY 2006 for chemical defense research.



NIAID Strategic Plan for Biodefense Research



NIAID Biodefense Research Agenda for CDC Category A Agents



NIAID Biodefense Research Agenda for CDC Category A Agents

Progress Report



August 2003



NIAID Biodefense Research Agenda for Category B and C Priority Pathogens



NIAID Biodefense Research Agenda for Category B and C Priority Pathogens

Progress Report




June 2004



January 2003



Therapeutics




Vaccines



Diagnostics

**Biodefense
Research
Priorities**




**Basic Research
(including Genomics)**




**Expansion of
Research Capacity**

Expansion of Biodefense Research Capacity



Basic Research in Biodefense: Progress and Priorities



Countermeasure Development: Key Achievements

Smallpox

- More than 300 million doses of smallpox vaccine now available
- "Next-generation" vaccine (MVA) in advanced testing
- Antiviral drug development, e.g. oral cidofovir

Anthrax

- New vaccine (rPA) tested and procured under Project Bioshield
- Development of novel antitoxins, e.g. monoclonal/polyclonal antibodies

Countermeasure Development: Key Achievements (continued)

Ebola

- **Vaccine in human trials at NIAID Vaccine Research Center**


Botulinum Toxin

- **Development of vaccine and monoclonal/polyclonal antibodies**

Influenza

- **Development of vaccines against potential pandemic strains**

Countermeasure Development: A Changing Paradigm



San Francisco Chronicle

NORTHERN CALIFORNIA'S LARGEST NEWSPAPER

FEBRUARY 18, 2002

Bioterror Funds a Boon for Public Health

**Experts say research will apply to
fighting infectious diseases**

Global Examples of Emerging and Re-Emerging Infectious Diseases

